Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Pharmacy chains should pay $878 million for opioid epidemic role, Ohio counties say

Published 05/10/2022, 06:08 AM
Updated 05/10/2022, 02:36 PM
© Reuters. FILE PHOTO: People walk by a CVS pharmacy store in Manhattan, New York City, New York, U.S., November 17, 2021. REUTERS/Andrew Kelly/

By Grant Segall and Dietrich Knauth

CLEVELAND (Reuters) -A lawyer for two Ohio counties said on Monday that CVS Health Corp (NYSE:CVS), Walgreens Boots Alliance (NASDAQ:WBA) Inc and Walmart (NYSE:WMT) Inc should fund an $878 million plan to address the opioid crisis there, as a first-of-its-kind trial got underway to determine the pharmacy chains' contribution.

A federal jury decided in November that the companies created a public nuisance by flooding Ohio's Lake and Trumbull counties with addictive prescription pain pills that wound up on the black market, in the first trial the pharmacy chains faced over the crisis.

Now, the counties want the companies to fund a $878 million five-year plan that Mark Lanier, a lawyer representing the counties, said on Monday was aimed at solving the opioid crisis rather than allocating blame.

Lanier's remarks came at the start of a two-week trial before U.S. Judge Dan Polster in Cleveland, who will decide how the companies should correct a public nuisance caused by prescription opioids.

"I've been tasked to do something that no other federal judge in our country has been tasked to do," Polster said at the start of a non-jury trial.

CVS, Walgreens and Walmart have denied the counties’ claims and said they would appeal the November verdict. The companies have offered to fund a one-year program to buy back unused prescription opioid drugs in the two counties. They argue that Ohio's public nuisance law only requires them to stop the nuisance identified by the jury - an oversupply of prescription drugs - and not to address all of its harmful effects on the communities.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The companies argued that if they must do more than buy drugs back, they should not be forced to cover costs related to illegal drug use.

The counties have argued that illegal drug use must be addressed at the trial, since addictions caused by the oversupply of prescription drugs created a market for illicit drugs like heroin and synthetic fentanyl.

The U.S. opioid epidemic has caused more than 500,000 overdose deaths over two decades, according to government data. More than 3,300 opioid lawsuits have been filed nationally against drugmakers, distributors and pharmacy chains, leading to a recent wave of proposed settlements.

The Ohio counties’ public nuisance theory has rarely been tested at trial, and has had mixed results in other courts.

Oklahoma's top court on Nov. 9 overturned a $465 million judgment against Johnson & Johnson (NYSE:JNJ), and a California judge in November ruled in favor of four drugmakers in a case brought by several large counties.

A New York jury in December found drugmaker Teva Pharmaceutical Industries (NYSE:TEVA) Ltd responsible for causing a public nuisance in the state, although the amount Teva must pay will be determined in a trial later in 2022.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.